摘要:
The present invention provides a recombinant antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a CH1 constant region fragment located between a first and second variable domain, and a third variable domain linked directly or indirectly to the first or second variable domain, with the proviso that the heavy chain only contains one CH1 and only contains three variable domains, and a light chain comprising at least a CL domain located between a first and second variable domain, and a third variable domain linked directly or indirectly to the first or second variable domain, with the proviso that the light chain only contains one CL domain and only contains three variable domains, and wherein said heavy and light chains are aligned to provide a first binding site formed by the first variable domains in the light and heavy chain, a second binding site formed by the second variable domains in the light and heavy chain, and a third binding site formed by the third variable domains in the light and heavy chain.
摘要:
The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.
摘要:
The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
摘要:
The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
摘要:
The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
摘要:
The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
摘要:
The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
摘要:
A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab′ fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab′ fragment and one or more single domain antibodies which may be stabilised by a disulfide bond therebetween.
摘要:
The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
摘要:
The present invention relates to improved methods for the selection of appropriate human acceptor framework regions for non-human (donor) antibodies and methods for obtaining humanized antibodies of high affinity using such acceptor frameworks.